The antiviral drug remdesivir — which President Trump received during his recent bout with the coronavirus — has no significant effect on patients’ chances of survival, according to a report about a clinical trial by the World Health Organization.
Results from the WHO’s Solidarity trial, which studied remdesivir and three other potential drug regimens, found that none of them “substantially affected mortality” or reduced the need for a ventilator, reported the Financial Times, which obtained a copy of the report.
The study of 11,266 hospitalized patients included hydroxychloroquine and an anti-HIV combination drug of lopinavir/ritonavir — which were stopped in June after they proved ineffective — and interferon.
“These remdesivir, hydroxychloroquine, lopinavir and interferon regimens appeared to have little effect on in-hospital mortality,” the study found, according to the Financial Times.
Remdesivir was developed by US drugmaker Gilead Sciences, initially as a potential medicine to treat Ebola.
It received partial approval for use after a trial by the US National